Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial

Clicks: 359
ID: 272487
2015
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #63 of 161 articles by views in Lancet (London, England)

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 161 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Merck & Co, Inc.
Reference Key
e2015lancetefficacy Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Lawitz E;Gane E;Pearlman B;Tam E;Ghesquiere W;Guyader D;Alric L;Bronowicki JP;Lester L;Sievert W;Ghalib R;Balart L;Sund F;Lagging M;Dutko F;Shaughnessy M;Hwang P;Howe AY;Wahl J;Robertson M;Barr E;Haber B;;
Journal Lancet (London, England)
Year 2015
DOI
DOI not found
URL
http://www.ncbi.nlm.nih.gov/pubmed/25467591
Keywords
hepatitis c National Center for Biotechnology Information NCBI NLM MEDLINE RNA humans pubmed abstract nih national institutes of health national library of medicine treatment outcome research support non-u.s. gov't adult female male adolescent aged middle aged young adult Drug Administration Schedule Comparative Study 80 and over Clinical Trial Randomized Controlled Trial Multicenter Study drug therapy combination viral load ribavirin / administration & dosage* viral / blood* phase ii chronic / complications chronic / drug therapy* antiviral agents / administration & dosage* treatment failure polyethylene glycols / therapeutic use hepacivirus / genetics interferons / therapeutic use sulfonamides quinoxalines / administration & dosage* eric lawitz liver cirrhosis / etiology* pmid:25467591 doi:10.1016/s0140-6736(14)61795-5 edward gane barbara haber amides benzofurans / administration & dosage* carbamates cyclopropanes imidazoles / administration & dosage*

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.